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Colon cancer is the second most lethal cancer; approximately 600,000 people die of it
annually in the world. Colon carcinogenesis generally follows a slow and stepwise process
of accumulation of mutations under the influence of environmental and epigenetic factors.
To adopt a personalized (tailored) cancer therapy approach and to improve current strate-
gies for prevention, diagnosis, prognosis, and therapy overall, advanced understanding
of molecular events associated with colon carcinogenesis is necessary. A contemporary
approach that combines genetics, epigenomics, and signaling pathways has revealed many
genetic/genomic alterations associated with colon cancer progression and their relation-
ships to a genomic instability phenotype prevalent in colon cancer. In this review, we
describe the relationship between gene mutations associated with colon carcinogene-
sis and a genomic instability phenotype, and we discuss possible clinical applications of
genomic instability studies. Colon carcinogenesis is associated with frequent mutations in
several pathways that include phosphatidylinositol 3-kinase, adenomatous polyposis coli,
p53 (TP53), F-box and WD repeat domain containing 7, transforming growth factor-β, chro-
mosome cohesion, and K-RAS. These genes frequently mutated in pathways affecting
colon cancer were designated colon cancer (CAN) genes. Aberrations in major colon CAN
genes have a causal relationship to genomic instability. Conversely, genomic instability
itself plays a role in colon carcinogenesis in experimental settings, as demonstrated in
transgenic mouse models with high genomic instability. Thus, there is a feedback-type
relationship between CAN gene mutations and genomic instability.These genetic/genomic
studies have led to emerging efforts to apply the knowledge to colon cancer prognosis and
to targeted therapy.
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INTRODUCTION: INCREASING IMPORTANCE OF MOLECULAR
ANALYSES OF COLON CANCER
Colorectal cancer (CRC) is a common epithelial neoplasia world-
wide, with about 1.2 million newly diagnosed cases and over
600,000 fatalities each year. Tens of millions of individuals identi-
fied with colon polyps are at high risk for CRC. In the US, CRC is
the second most lethal cancer; 50,830 people are predicted to die
of it during 2013 [American Cancer Society (ACS), 2013]. Among
all colon cancer cases, approximately 20% have a familial or con-
genital mutation(s) in gene(s) that increase colon cancer risk, and
the cancers tend to develop at an earlier stage of life. The remain-
ing majority (80%) is sporadic, with no obvious genetic causes,
and these cases tend to develop later in life, suggesting roles for
environmental factors, for time and for accumulation of multiple
yet specific genetic mutations and/or for epigenetic alterations. In
general, development of sporadic cancer is a slow, age-influenced
process with progressive acquisition of genetic mutations and/or
epigenetic alterations under the influence of environmental and
other external factors. In the colon, normal tissues acquire cer-
tain mutations, and develop into hyperplastic epithelia, then into
early adenomas. Early adenomas develop into intermediate and
late adenomas, then into carcinomas with additional key gene
mutations, activation of oncogenes, loss and gain of chromo-
somes, and/or chromosome amplifications (Fearon and Vogel-
stein, 1990). This process usually takes decades. Transition from
carcinoma-to-metastatic CRC takes an additional 2–3 years.
The cancer stage is well correlated with the current cure rate.
Early Stage CRC (stage I and II; localized cancers usually at the
adenoma-carcinoma stage) can be cured at a relatively high rate:
80–95% for stage I, 55–80% for stage II. In advanced stages such
as metastatic stage IV, the cure rate drops to an unsatisfactory 5–
10%. Unfortunately, only around 40% of colorectal cancers are
found at the early, relatively curable stages (stages I–II) [American
Cancer Society (ACS), 2013]. From the statistics, we can iden-
tify several points for improvement and envision approaches to
reduce colon cancer-mediated death overall. It is important to
note that efficient execution of these approaches requires infor-
mation regarding the nature of the mutations each colon cancer
has acquired. These general approaches and specific examples rel-
evant to CRC include the following: (i) developing methods to
identify high-risk groups among the entire population. For CRC,
identification of molecular markers that indicate high CRC risk is
needed for screening purposes. (ii) Effective use of prevention. In
addition to markers, molecular targets for CRC prevention agents
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(e.g., drugs, natural products, dietary components) need to be
identified. (iii) Improvements in screening, detection, and diagno-
sis for early stage cancers. For CRC detection and screening, visual
inspection with colonoscopy is very effective, yet the method is
not favored by a majority of patients due to psychological resis-
tance and high cost. Developing a non-invasive marker (e.g., blood
marker) would allow development of alternative screening meth-
ods. (iv) Addressing unmet clinical needs for therapy. In recent
years, it has become possible to monitor molecular markers in a
given cancer tissue (e.g., in biopsy samples) and to use the infor-
mation to make a prognosis or to establish a therapeutic strategy
for personalized (tailored) treatments. To perform personalized
cancer therapy, information on development and progression of
individual cancers is required. For example, in the case of breast
cancer, Her-2 status is crucial information for determining applic-
ability of the anti-Her-2 antibody trastuzumab/Herceptin (Tsang
and Finn, 2012). Thus there is an increasing need to identify
accurate diagnostic and prognostic markers along with therapeu-
tic targets. Contemporary synthetic biological approaches (com-
bining genetics, genomics, proteomics, and bioinformatics) have
revealed a great deal of information about the molecular changes in
CRC. In this review, we will discuss the relationship between gene
mutations associated with colon carcinogenesis and a genomic
instability phenotype highly prevalent in colon cancer; and we will
discuss emerging translational attempts at prognosis and targeted
therapy for colon cancer based on studies of genomic instability.
THE “VOGELGRAM”
Cancer develops in a stepwise manner, and each step is associ-
ated with changes at the molecular level. In 1990, Fearon and
Vogelstein proposed a progressive development model of colon
cancer and presented some of the key genetic changes associ-
ated with the stages of progression (Fearon and Vogelstein, 1990;
Grady, 2004) (Figure 1). This type of schematic presentation of
the correlation between genetic/genomic changes and stages of
colon cancer progression is nicknamed a “Vogelgram.” The model
is widely accepted, and newer information from genomics, cyto-
genetics, and tumor mass sequencing is being added to advance
our understanding (e.g., Wood et al., 2007; Chittenden et al., 2008;
Brosens et al., 2010). Inactivation of the tumor suppressor Adeno-
matous polyposis coli (APC) is observed at an early stage of colon
tumor development. Activation of the K-RAS oncogene is associ-
ated with transition from early adenoma to intermediate adenoma.
Genomic level changes such as loss of chromosome 18, along with
loss of Deleted in Colon Cancer (DCC) loci, are observed in tran-
sition from intermediate adenoma to late adenoma. Loss of tumor
suppressor p53 (TP53) and gain of chromosome 8q are associated
with late adenoma-carcinoma transition. Gaining the ability to
metastasize requires additional changes. Loss of chromosome 8p
is associated with the carcinoma-to-metastatic transition (Fearon
and Vogelstein, 1990; Kinzler and Vogelstein, 1996; Grady, 2004).
In the sequence of events, numerical and structural centrosome
changes (which would lead to genomic instability; see later section)
are observed as early and stable events (Kayser et al., 2005). Since
APC mutations that can lead to genomic instability also map as
early events, these results suggest that genomic instability begins
early in CRC development. Genomic instability has mapped early
in ulcerative colitis-related CRC as well (Willenbucher et al., 1999).
GENOMIC INSTABILITY IN COLON CANCER
Cytogenetic studies [e.g., karyotyping, Fluorescence in situ
hybridization (FISH)] of colon cancers have shown a high degree
of genomic instability and aneuploidy. Genomic instability refers
to a range of genetic/genomic alterations from point mutations
to chromosome rearrangements, whereas aneuploidy is more nar-
rowly defined as having an abnormal number of chromosomes
without being polyploid.
There are two major categories of genomic instability in CRC:
Chromosome Instability (CIN) and Micro(mini)satellite Instabil-
ity (MIN). CIN is defined mainly from a functional/mechanistic
standpoint, and refers to a persistent high rate of chromosome
mis-segregation. CIN leads to changes in chromosome number
such as chromosome gain or loss. As such, CIN phenotype and
aneuploidy refer to a similar or identical condition. In contrast,
MIN is often defined from a phenotypical standpoint and refers
to repetitive DNA expansions and contractions in the cell. Molec-
ular causes of the MIN phenotype are DNA replication and repair
defects. Etiologically, CIN is more prevalent than MIN in CRC.
CIN was observed in approximately 85% of colon cancers, and
MIN was observed in the remaining 15% (Dunican et al., 2002).
Chromosome instability is caused mainly by failures in
the mitotic process (e.g., in chromosome transmission, at the
mitotic spindle checkpoint, in kinetochore-microtubule attach-
ment dynamics) and/or in the mitotic apparatus (e.g., kinetochore,
centrosome) that cause mitotic process failures. Among a variety
of defects that lead to a mitotic failure and CIN, a particularly
FIGURE 1 |The “Vogelgram” (modified from the original in Fearon
and Vogelstein, 1990). The original “Vogelgram” (Fearon and Vogelstein,
1990) mapped loss of chromosome 5q, 12p, 18q, and 17p, and mutations
on APC, K-RAS, DCC, and p53 in a sequential order of cancer progression,
although the importance of mutation accumulation, rather than sequential
order, was emphasized. DNA hypermethylation also was mapped in the
early adenoma stage. Later, gain of Chromosome 20 (Davison et al., 2005;
Wang et al., 2013), gain of chromosome 8q and loss of Chromosome 8p
(Bacolod and Barany, 2010), and mutation in DPC4/SMAD4 (Fleming et al.,
2013) were added.
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damaging defect in terms of genomic integrity is centrosome mis-
regulation. Centrosome mis-regulation can lead to an abnormal
number of centrosomes and multipolar mitosis can occur as a
result. As described in later sections, defects leading to centro-
some mis-regulation tend to be associated with carcinogenesis
[e.g., mutations in p53, Shugoshin 1 (Sgo1)]. In addition, many
cell cycle regulators [e.g., breast cancer 1 (BRCA1) and breast can-
cer 2 (BRCA2; Joukov et al., 2006), Retinoblastoma (Rb; Hernando
et al., 2004), forkhead box M1 (FoxM1; Laoukili et al., 2005), RE1-
silencing transcription factor (REST; Guardavaccaro et al., 2008);
Von Hippel Lindau (VHL; Thoma et al., 2009), Kruppel-like factor
(Hagos et al., 2009), Mdm2 (Wang et al., 2007), MdmX (Matija-
sevic et al., 2008), and RAN binding protein 1 (RanBP1; Tedeschi
et al., 2007)] are involved in generation of CIN directly or indi-
rectly. The precise mechanisms are not yet clear in many cases
(Thompson et al., 2010).
The MIN phenotype is characterized by repetitive DNA expan-
sions and contractions, and can be caused by defects in DNA
replication and repair systems, such as replication slippage,
mismatch-repair (MMR) impairment, or homologous recombi-
nation defects. MIN is associated with frequent DNA damage or
breaks, which can result in gross chromosomal rearrangements
such as translocations, duplications, inversions, or deletions. The
relationship between MIN and genomic instability was reviewed in
more detail elsewhere (e.g., Aguilera and Gómez-González, 2008).
It is to be noted that CIN and MIN are not mutually exclu-
sive. Some cell lines from the NCI 60 panel (60 cell lines derived
from cancers of 9 tissue origins that have been invaluable in vitro
models for cancer research and anti-cancer drug screening) have
both CIN and MIN. Examples include KM12, DU-145, SK-MEL-
2, and IGROV-1 cell lines (Roschke et al., 2003; Shoemaker, 2006).
It is conceivable that these cell lines harbor mutations both in
CIN-related gene(s) and in MIN-related gene(s).
Moreover, recent studies on mitotic errors using cell lines
revealed that CIN-causing mitotic errors, along with the extended
mitotic arrest often associated with them, also can result in DNA
damage, chromosomal rearrangements, and chromothripsis – i.e.,
the fragmentation of a chromosome and its subsequent highly
imperfect reassembly (Janssen et al., 2011; Crasta et al., 2012; Orth
et al., 2012). A recent report showed that CIN may arise through
DNA replication stress (Burrell et al., 2013). Thus, the distinction
between CIN and MIN may not be as strict as previously theorized
in terms of generation of DNA damage. Further investigation is
required to confirm the cell biological observations in animals or
humans.
Figure 2 shows a schematic diagram indicating when MIN,
CIN, aneuploidy, chromothripsis, and cell death (both cell destruc-
tion and senescent/replicative death) occur during the cell cycle.
Events causal to the MIN phenotype take place mainly in G1, S,
and G2 phases, whereas CIN becomes apparent during mitosis
FIGURE 2 | How MIN and CIN contribute to genomic instability.
Normal cell cycle progression follows G0/G1, S, G2, and M phases (shown
in the top with gray-shaded cells). MIN is caused by a defect in DNA repair
and/or replication, and is thought to take place mainly during G0/G1, S, or
G2 phases in the cell cycle (shown in blue). MIN-type chromosome
alteration or its underlying causes also can lead to mitotic errors and CIN
(Burrell et al., 2013). CIN is caused by an event in mitosis leading to a
chromosome segregation error (e.g., a kinetochore defect, a spindle
challenge, a mitotic spindle checkpoint defect, a chromosome cohesion
defect; shown in red). CIN also can be caused by an event in a pre-mitotic
phase that sets up a mitotic error (e.g., replication stress that can affect
mitotic chromosome structure, centrosome mis-regulation that results in
multipolar mitosis). CIN-mediated chromosome mis-segregation can lead
further to DNA damage, directly caused by cytokinesis machinery or in the
process of chromothripsis (Janssen et al., 2011; Crasta et al., 2012).
Failures in cytokinesis and subsequent p53-dependent removal of the cell
result in generation of a polyploid cell. Polyploidy can lead to aneuploid
offspring cells via multipolar mitosis (Shi and King, 2005). Since p53 is
involved in centrosome regulation and clustering in addition to removal of
aneuploid/polyploid cells, loss of p53 can permit a polyploid-multipolar
mitosis-aneuploid cycle, which would be highly detrimental to genomic
integrity.
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due to an event in mitosis (e.g., a defect in the spindle, the spindle
checkpoint, the kinetochore, or chromosomal structure) or in a
pre-mitosis phase (e.g., a defect in centrosome integrity or a DNA
replication defect in S phase).
In summary, genomic instability in CRC has been subdivided
classically into CIN and MIN, with CIN being more prevalent than
MIN. Yet, CIN and MIN are not mutually exclusive and can coin-
cide in cancer cells. Newer studies suggest that CIN can lead to
not only chromosome loss or gain but to DNA damage and/or to
chromothripsis, although it is unclear yet how frequent the events
are or how they are tolerated (or eliminated) in vivo.
CAN GENES AND GENOMIC INSTABILITY
Tumor mass-sequencing revealed that human colon cancers have
several sets of frequently mutated genes and pathways (Wood
et al., 2007; Chittenden et al., 2008). The frequently mutated
genes were designated as cancer (CAN) genes. The colonic CAN
genes/pathways include the signal transducer phosphatidylinosi-
tol 3-kinase (PI3K ), the tumor suppressor/gate keeper APC, the
tumor suppressor TP53, an SCF-E3 ubiquitin ligase complex
component F-box/WD repeat-containing protein 7 (FBXW7, also
known as hCDC4), the growth factor Transforming Growth Fac-
tor (TGF)-β, genes involved in chromosome cohesion, and the
RAS-GTPase family proto-oncogene K-RAS (Wood et al., 2007;
Barber et al., 2008; Chittenden et al., 2008). The high frequency of
mutations suggests that each pathway plays a significant role in car-
cinogenesis, and that the mutations function as driver mutations,
rather than as secondary passenger mutations. In many cases, the
functional significance of the mutations already was demonstrated
experimentally in cell biology studies. Each gene/pathway has
unique functions in different biological processes. However, sur-
prisingly, in almost all cases (except for K-RAS, over which there is
controversy), targeted in vitro manipulation of these colonic CAN
genes [e.g., with small inhibitory (si) or short hairpin (sh)RNA]
resulted in elevated genomic instability, directly, or indirectly.
PHOSPHATIDYLINOSITOL 3-KINASE
Phosphatidylinositol 3-kinases are a family of related intracellular
signal transducing enzymes capable of phosphorylating the three
position hydroxyl group of the inositol ring of phosphatidyli-
nositol. The PI3K kinase signaling can be antagonized by the
phosphatase/tumor suppressor Phosphatase and tensin homolog
(PTEN). Loss of function of PTEN leads to genomic instabil-
ity through its centrosome interaction (Shen et al., 2007; Liu
et al., 2008). Overexpression of oncogenic Met induces centrosome
amplification and CIN, and the effect is mediated by PI3K-Akt and
p53 (Nam et al., 2010).
ADENOMATOUS POLYPOSIS COLI
Mutations in the human APC tumor suppressor gene are linked
to Familial Adenomatous polyposis (FAP), an inherited cancer-
prone condition in which numerous polyps are formed in the
epithelium of the large intestine (Kinzler et al., 1991; Kinzler and
Vogelstein, 1996; Half et al., 2009). The APC protein functions as
a scaffold and physically interacts with a number of proteins rele-
vant to carcinogenesis; thus it acts as a signaling hub. Of particular
importance for colonic carcinogenesis is the APC-interacting pro-
tein beta-catenin, a Wnt signaling component. When the Wnt
pathway is stimulated, beta-catenin activates transcription fac-
tor (TCF)-dependent transcription of Wnt-target genes such as
Cyclin D1 (CCND1), MYC, and EphrinB (EphB), and promotes
cell proliferation. Loss of APC influences cell adhesion, cell migra-
tion, cytoskeleton, and chromosome segregation (Aoki and Taketo,
2007).
Adenomatous polyposis coli truncations (both MIN1–850 and
Apc1638T alleles) led to chromosomal instability in mouse embry-
onic stem cells (Fodde et al., 2001). Binding of APC to micro-
tubules increased microtubule stability in vivo and in vitro, sug-
gesting a role of APC in microtubule stability (Zumbrunn et al.,
2001). APC truncation acted dominantly to interfere with micro-
tubule plus-end attachments and to cause a dramatic increase
in mitotic abnormalities (Green and Kaplan, 2003), and the
effect was mediated by APC-EB1 interaction (Green et al., 2005;
Draviam et al., 2006). Thus, cancer cells with APC mutations
have a diminished capacity to correct erroneous kinetochore-
microtubule attachments, which would account for the wide-
spread occurrence of CIN in tumors (Bakhoum et al., 2009).
In addition, abrogation of the spindle checkpoint function was
reported with APC loss of function. Knockdown of APC with
siRNA indicated that loss of APC causes loss of mitotic spin-
dle checkpoint function by reducing the association between
the kinetochore and checkpoint proteins Bub1 and BubR1, and
that it reduces apoptosis and induces polyploidy (Kaplan et al.,
2001; Dikovskaya et al., 2007; Rusan and Peifer, 2008). Poly-
ploidy is a major source for aneuploidy since it can lead to
multipolar mitosis (Shi and King, 2005). Thus, APC mutation
or loss of function can influence CIN in at least three man-
ners: by diminishing kinetochore-microtubule interaction, by the
loss of mitotic checkpoint function and by generating polyploid
cells.
p53
Targeted inactivation of p53 in HCT116 cells and in primary
human fibroblasts led to no increased rates of numerical or
structural chromosomal instabilities, although a tendency toward
tetraploidization was observed (a 3.5-fold increase, subtle yet sig-
nificant) (Bunz et al., 2002). The result suggests that p53 inactiva-
tion by itself may have little effect on genomic instability. However,
tetraploid cells can be a rich source for aneuploidy,especially if they
go through multipolar mitosis subsequently (Shi and King, 2005).
p53 Is involved in centrosome clustering and prevents multipolar
mitosis in tetraploid cells (Yi et al., 2011). Thus, loss of p53 can
increase the risk of genomic instability by generating or permitting
tetraploid cells that can go through multipolar mitosis.
In tumors, loss or mutational inactivation of p53 is associated
with abnormal amplification of centrosomes (Carroll et al., 1999).
Subsequent reports suggest that p53 is involved in the centroso-
mal duplication cycle, and that the loss of p53 can lead to genomic
instability through deregulation of the centrosome duplication
cycle and failure to undergo cytokinesis (Tarapore and Fukasawa,
2002; Tomasini et al., 2008). Also, p53 is involved in p21-dependent
cell cycle arrest and/or cell death after failed mitosis; thus, the loss
of p53 is involved in tolerance of aneuploidy or polyploidy (Tara-
pore and Fukasawa, 2002; Senovilla et al., 2009; Thompson and
Compton, 2010; Vitale et al., 2010).
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Therefore, loss of p53 can contribute to genomic instabil-
ity through at least three pathways: (a) increasing tetraploid
cells that can go through multiploar mitosis, (b) centrosomal
mis-regulation that also can lead to multipolar mitosis, and (c)
permitting survival of aneuploid and tetraploid cells.
F-BOX/WD REPEAT-CONTAINING PROTEIN 7
F-box/WD repeat-containing protein 7 (also known as FBX7,
hCDC4) is the substrate recognition subunit of the SCF-E3 ubiq-
uitin ligase complex, and as such, can target a wide variety of
biological processes through ubiquitin/proteasome pathways. The
major substrates relevant to carcinogenesis include Cyclin E, MYC,
JUN, and Notch (Perez-Losada et al., 2005; Welcker and Clurman,
2008). Genetic inactivation of FBXW7, by means of targeted dis-
ruption of the gene in karyotypically stable colorectal cancer cells,
results in a phenotype associated with micronuclei and chromo-
somal instability (Rajagopalan et al., 2004). This phenotype was
associated with a defect in the execution of metaphase and sub-
sequent transmission of chromosomes, and was dependent on
Cyclin E, a target of FBXW7-SCF-E3 ubiquitin ligase. Deregula-
tion of Cyclin E also is known to cause genomic instability through
S-phase delay (Spruck et al., 1999). In breast cancer, high levels of
low molecular weight Cyclin E isoforms may contribute to cellu-
lar transformation and genomic instability by shortening mitotic
progression (Bagheri-Yarmand et al., 2010). Additionally, cen-
trosome duplication during G1/S-phase requires Cyclin E/Cdk2
activity, and Cyclin E mis-regulation contributes to centrosome
duplication error (Fukasawa, 2008; Hanashiro et al., 2008; Shi-
mada and Komatsu, 2009). Thus an FBXW7 defect can influence
genomic instability through Cyclin E mis-regulation, cell cycle
mis-coordination, and centrosome duplication error.
TRANSFORMING GROWTH FACTOR-β
Transforming growth factor-β is a multi-functional cytokine/growth
factor. Aberrations of TGF-β signaling have been linked to genomic
instability. TGF-β−/− mouse keratinocytes showed aneuploidy
and accumulation of chromosomal aberrations, which could
be suppressed by the addition of TGF-β in a TGF-β receptor-
dependent manner (Glick et al., 1996). v-ras (Ha)-transduced
primary TGF-β1−/− keratinocytes and keratinocytes expressing
a TGF-β type II dominant-negative receptor transgene have sig-
nificantly higher frequencies of spontaneous transformation than
do control genotypes (Glick et al., 1999). In cervical cancer cells,
the introduction of TGF-β1 in the culture medium induced
crisis, which was associated with massive chromosomal end-
to-end fusions and other structural aberrations, suggesting an
involvement of telomere function in TGF-β-mediated CIN (Deng
et al., 2008). However, information for the mechanism connecting
TGF-beta to CIN or MIN has been largely lacking.
CHROMOSOME COHESION
Chromosome cohesion is maintained by a ring-shaped cohesin
complex that wraps around sister chromosomes, and by other
proteins that support the function of or interaction with the
cohesin complex, including Sgo1 (“Guardian God” 1 in Japan-
ese) and securin (Oliveira and Nasmyth, 2010). Many yeast CIN
mutants were identified later as chromosome cohesion mutants
(Thompson et al., 2010). Mutations in cohesin complex sub-
units in humans are observed in Cornelia de Lange syndrome, a
rare, genetically heterogeneous disorder affecting multiple organs
and systems during development (Liu and Krantz, 2009). Over-
expression of human WAPL protein, a cohesin binding protein,
was found in cervical cancers and correlated significantly with
the grade of the malignancy (Oikawa et al., 2004, 2008). WAPL
involvement in cervical carcinogenesis may be due partially to
the resulting chromosomal instability (Ohbayashi et al., 2007).
Sgo1 was identified first as a protector of the centromeric cohesin
complex from premature degradation or removal during mito-
sis (Wang and Dai, 2005; Watanabe and Kitajima, 2005). Loss of
Sgo1 leads to premature chromosome segregation during mito-
sis and spindle checkpoint-mediated mitotic delay; it leads to
genomic instability in yeast, mice, and human cells (Salic et al.,
2004; McGuinness et al., 2005; Wang et al., 2008; Iwaizumi et al.,
2009). Later, Sgo1 and cohesin were shown to be involved also in
the maintenance of centrosomal integrity (Schöckel et al., 2011).
Thus, normal functions of these frequently mutated CAN genes
are directly or indirectly involved in genomic fitness and pre-
vention of CIN. Abnormalities in chromosome structure, and in
structure and function of the mitotic apparatus (e.g., centrosome,
kinetochore, telomere), often are caused by aberrant CAN gene
functions (Figure 3; Table 1).
K-RAS
In contrast to other prominent CAN genes, a direct connection
of K-RAS activation to genomic instability has been controversial.
Several experiments using cell lines to express activated H-RAS
showed an increase in genomic instability (Ichikawa et al., 1990;
Denko et al., 1994; Saavedra et al., 2000; Woo and Poon, 2004;
Knauf et al., 2006), suggesting that expression of activated K-RAS
(which presumably functions in a very similar or identical manner
to the isoform H-RAS) (Baker et al., 2013) may have a similar effect
and be able to promote genomic instability by itself. However, the
role of K-RAS in vivo in carcinogenesis and in genomic instabil-
ity has remained unclear, in part because the experiment is not as
straightforward as knockdown or inhibition experiments (Castag-
nola and Giaretti, 2005). Some transgenic mouse-based studies
tackled this question. Luo et al. (2011) reported on the combined
effect of treatment with the DNA-alkylating colon carcinogen
DMH andCre-LoxP-mediated K-rasG12D activation in colon car-
cinogenesis in mice, and concluded that mutant K-ras significantly
promotes DMH-induced colorectal carcinogenesis, resulting in
distinct changes in cell signaling and proliferation, but that it
does not alter chromosome stability in the tumors. Yet, another
study showed that combining mutations in p53 (Trp53R172H) and
K-RAS (G12D) in a PDX-1-Cre pancreatic cancer mouse model
resulted in rapid development of invasive and metastatic pan-
creatic ductal adenocarcinoma with a high degree of genomic
instability. The genomic instability was accompanied by frequent
centrosomal defects and multipolar mitosis, which may have been
caused by the p53 defect (Hingorani et al., 2005). Thus, K-RAS
activation at least exacerbated genomic instability in the pancreas.
Other mouse model studies have shown that mutant K-ras accel-
erates intestinal carcinogenesis on both a mutant Apc background
and anMut SHomolog 2 (Msh2)-null background (Luo et al., 2007,
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FIGURE 3 | Defects in major colonic CAN genes are causal to high
genomic instability in the colon. Mass-sequencing projects have
identified frequently mutated genes and pathways in colon cancer. They
are designated as CAN (cancer) genes (Wood et al., 2007; Chittenden
et al., 2008; Brosens et al., 2010). Colonic CAN genes/pathways include
p53, PI3K, APC, FBXW7, TGF-β, and chromosome cohesion. Studies have
indicated that each CAN gene mutation can lead to genomic instability
either by itself or in concert with other mutations (see text). This effect
would explain why nearly all advanced colon cancers show a high degree
of genomic instability.
2009). Since both APC and Msh2 mutations can cause genomic
instability by themselves (Apc : CIN; Msh2: MIN), a role of K-ras
mutation in the gastrointestinal (GI) tract may be at least to exacer-
bate already existing genomic instability, although K-ras mutation
alone may be insufficient to generate tumor aneuploidy. The dif-
fering results between tumors of the GI tract and pancreas may be
a matter of organ specificity.
In summary, most of the frequently mutated genes and path-
ways involved in colon carcinogenesis (colonic CAN genes) are
involved in genomic instability or, in the case of K-ras, at least
exacerbate it.
INSIGHTS FROM TRANSGENIC MOUSE MODELS
In vitro studies described above support the notion that aberra-
tions in major colonic CAN genes lead to or facilitate genomic
instability. Is genomic instability itself causal to and/or enhancing
of colon carcinogenesis in vivo? To address this question, several
transgenic mouse models were generated in which genes involved
in the processes associated with genomic instability were targeted
to test for effects on carcinogenesis (Foijer et al., 2008; Ricke et al.,
2008; Rao et al., 2009; Schvartzman et al., 2010).
Apc MOUSE MODEL AND COLON CANCER
The first mouse model that contained a mutation in the Apc gene
was designated multiple intestinal neoplasia (Min) (Su et al.,1992).
This mouse was obtained in N -ethyl-N -nitrosourea an (ENU)
mutagenesis screen. Min mice were found to have a nonsense
mutation at the region corresponding to codon 850 of the Apc
gene. The Min mutation results in a truncated protein of 850
amino acids. Apc Min heterozygotes (Apcmin/+) are born nor-
mally but have a reduced average lifespan of 150 days. These
mice can develop more than 100 adenomas in the small intes-
tine, depending on the genetic background. On average, the mice
developed between 18 and 62 tumors per mouse in the small
intestine but only 0–4 tumors per mouse in the colon. All of the
histopathologically classified tumors in the small intestine and
those in the colon were adenomas (adenomatous polyps), with no
evidence of local invasion of the lamina propria. The Apcmin/+
mouse model has been used in numerous studies of GI tract
carcinogenesis, alone or in combination with other mutations or
drugs (Taketo, 2006; Rosenberg et al., 2009; Taketo and Edelmann,
2009).
MICRO(MINI)SATELLITE INSTABILITY MODELS AND COLON
CANCER
Micro(mini)satellite instability is observed in a significant pro-
portion (15%) of human colon cancer. Up to 5% of human colon
cancers diagnosed in the US are categorized as hereditary non-
polyposis colorectal cancer (HNPCC) with MIN phenotype, and
causal gene mutations have been identified. Mutations in the two
human DNA repair genes MSH2 and Mut L Homolog 1 (MLH1)
are responsible for HNPCC, as well as for a significant number
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Table 1 | Cancer genes and pathways involved in CIN.
Major colonic CAN
genes/pathways
Function Involvement in CIN
p53 Transcription factor Tetraploid generation (Bunz et al., 2002)
Tumor suppressor Centrosome mis-regulation (Carroll et al., 1999; Tarapore and Fukasawa, 2002;
Tomasini et al., 2008)
Tolerance to aneuploidy/polyploidy (Tarapore and Fukasawa, 2002; Senovilla et al.,
2009; Thompson and Compton, 2010; Vitale et al., 2010; Yi et al., 2011)
PI3K/PTEN Signal transduction
kinase/phosphatase
Centrosome mis-regulation (Shen et al., 2007; Liu et al., 2008; Nam et al., 2010)
APC Scaffold protein, signaling hub Kinetochore-microtubule attachment (Green and Kaplan, 2003; Green et al., 2005;
Draviam et al., 2006; Bakhoum et al., 2009)
Spindle checkpoint defect (Kaplan et al., 2001; Dikovskaya et al., 2007; Rusan and
Peifer, 2008)
Polyploid cell generation (Dikovskaya et al., 2007; Rusan and Peifer, 2008)
FBXW7 A component of SCF ubiquitin
ligase complex
Centrosome mis-regulation via Cyclin E (Fukasawa, 2008; Hanashiro et al., 2008;
Shimada and Komatsu, 2009)
Transcription factor mis-regulation (Perez-Losada et al., 2005; Welcker and
Clurman, 2008)
Cell cycle mis-regulation (Spruck et al., 1999; Bagheri-Yarmand et al., 2010)
TGF-β Cytokine, Growth factor Telomere dysfunction (Deng et al., 2008)
Chromosome cohesion
(cohesins, Sgo1)
Chromosome structure, centriole
engagement/centrosome integrity
Premature Chromosome separation (Salic et al., 2004; McGuinness et al., 2005;
Wang et al., 2008; Iwaizumi et al., 2009; Yamada et al., 2012)
Centrosome mis-regulation (Schöckel et al., 2011; Yamada et al., 2012)
K-RAS Signaling GTPase, protein
modification
Accelerate carcinogenesis in concert with other mutations (Hingorani et al., 2005;
Luo et al., 2007, 2009, 2011)
May cause genomic instability by itself (H-RAS studies: Ichikawa et al., 1990;
Denko et al., 1994; Saavedra et al., 2000; Woo and Poon, 2004; Knauf et al., 2006)
of sporadic colorectal cancers with MIN (Kinzler and Vogelstein,
1996; Half et al., 2009). The observation raises questions about
the role of these DNA repair proteins and the homologs in the
initiation and progression of colorectal cancer. To address these
questions, mice with inactivating mutations in all of the known
mutS and mutL homologs have been generated (i.e., Msh2, Msh3,
Msh4, Msh5, Msh6, Mlh1, Pms1, and Pms2; Heyer et al., 1999).
Analyses of the mouse phenotypes revealed a role for some of
the DNA mismatch-repair genes in lymphoma and GI tract car-
cinogenesis and in mammalian meiosis. Among the transgenic
mutant mice, msh2, msh3, msh6, and mlh1 mice showed cancer
development in the GI tract.
Mut S HOMOLOG 2
Mut S homolog 2-deficient mice are fertile and develop normally.
Msh2 homozygous mutant mice (−/−) have a reduced life span
compared with wild type and heterozygote (−/+) mutant animals.
Fifty percent of the animals die by the age of 6 months and all ani-
mals were dead by 12 months of age due to T-cell lymphomas.
Those MSH2-deficient mice that survive more than 6 months
develop GI and skin tumors. The GI tumors found in these stud-
ies were classified as adenomas and carcinomas (Reitmair et al.,
1996).
Msh6 AND Msh3
In human cells, the two protein complexes consisting of MSH2–
MSH3 and MSH2–MSH6 appear to be responsible for the
recognition of mispaired bases during MMR. The MSH2–MSH6
complex recognizes single nucleotide and small insertion/deletion
mismatches, and the MSH2–MSH3 complex recognizes small
insertion/deletion mismatches (Guerrette et al., 1998). Mice defi-
cient in MSH6 are fertile and develop a cancer susceptibility
syndrome similar to Msh2 mutant mice (Edelmann et al., 1997).
A majority of these mice develop invasive B and T-cell lymphomas
and GI tumors within their first year. A surprising difference
between Msh2- and Msh6-deficient mice is the lack of microsatel-
lite instability in Msh6-deficient tumors. The MIN analysis data
implies that the Msh6 defect-mediated MIN by itself may not
be responsible for tumorigenesis but that it may provide cancer
predisposition (Edelmann et al., 1997).
Cells from Msh3−/− mice are defective in repair of inser-
tion/deletion mismatches but can repair base-base mismatches.
The survival rate of Msh3−/− mice was not significantly differ-
ent from that of wild type, though the Msh3−/− mice developed
tumors at a late age (Edelmann et al., 2000). Msh3−/− msh6
double mutant mice showed a GI tract cancer-prone phenotype
nearly identical to that of msh2 mice, indicating functional overlap
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between msh3 and msh6 proteins (de Wind et al., 1999; Edelmann
et al., 2000).
Mut L HOMOLOG 1
Targeted inactivation of the mutL homolog Mlh1 in mice leads
to infertility and tumor susceptibility. Fifty percent of the MLH1-
deficient animals die prior to 6 months of age and all animals die
by 13 months of age because of the development of T-cell lym-
phomas and GI tumors. GI tumors were found throughout the
small intestine and ranged from adenomas to early invasive car-
cinomas. Typically, one to two GI tumors were found per mouse
(Edelmann et al., 1999). Cases of a human MLH1 kindred that
carried a homozygous MLH1 mutation also were reported. These
patients died at a very young age and developed leukemias and/or
lymphomas and neurofibromatosis type I, showing resemblance
to the mouse phenotype (Ricciardone et al., 1999; Wang et al.,
1999).
Hegan et al., compared the degree of genomic instability in mice
deficient for Pms2, Mlh1, Msh2, Msh3, or Msh6 or both Msh2 and
Msh3 or both Msh3 and Msh6 using two reporter gene systems.
Among the single nullizygous (−/−) mice, Mlh1, and Msh2 defi-
ciency produced the greatest instability, whereas Msh3 deficiency
generated the least. Compared with wild type, the double mutant
mice deficient for both Msh2 and Msh3 or deficient for both Msh3
and Msh6 displayed the largest increases in mutation frequencies
of all the groups (Hegan et al., 2006). Thus, at least in some cases,
the degree of genomic instability is correlated with GI tract cancer
predisposition in vivo.
CHROMOSOME INSTABILITY MODELS AND COLON CANCER
Chromosome instability model mice were generated by targeting
mitotic processes. The targets included mitotic spindle check-
point components Mad1 (Iwanaga et al., 2007), Mad2 (Dobles
et al., 2000; Michel et al., 2001), Bub1 (Baker et al., 2009; Baker
and van Deursen, 2010; Ricke et al., 2011, 2012), BubR1 (Baker
et al., 2004; Wang et al., 2004), Bub3 (Kalitsis et al., 2000),
mitotic motor CenpE (Weaver et al., 2007), and chromosome
cohesion/centrosome integrity protector Sgo1 (Wang et al., 2008;
Yamada et al., 2012) (reviewed in Foijer et al., 2008; Ricke et al.,
2008; Rao et al., 2009; Schvartzman et al., 2010). As predicted,
the transgenic mice commonly showed an increase in genomic
instability at the cellular level, demonstrated via fibroblast culture,
blood cell karyotyping, and/or FISH analyses of tissues. Cancer-
prone phenotypes were observed, especially in liver and lung, albeit
the degree was modest in most strains. Although each targeted
gene may have an additional role outside of mitosis, the results
collectively point to a conclusion that CIN and aneuploidy can be
causal to carcinogenesis. A CenpE mutation functioned as both an
oncogenic and a tumor suppressor, suggesting that carcinogenesis
in the models is a result of imbalance between pro-carcinogenic
and anti-carcinogenic effects rather than from a straightforward
drive toward cancer (Weaver et al., 2007). The duality may provide
a proof-of-principle for cancer therapy that targets the mitotic
checkpoint and elevates chromosome mis-segregation (Janssen
et al., 2009; Colombo and Moll, 2010). The relationship to car-
cinogenesis in the GI tract was investigated in two CIN strains,
BubR1 and Sgo1.
BubR1
Human BubR1 is an essential component of the mitotic spin-
dle checkpoint (Chan et al., 1999). Congenital mutation in the
BubR1 gene was linked to mosaic variegated aneuploidy (MVA), a
rare cancer-susceptible disorder (Hanks et al., 2004; Suijkerbuijk
et al., 2010). In mice, BubR1 complete knockout results in death
in utero before E8.5 (Dai et al., 2004). Depending on the allele
and the degree of the loss of the function, the mouse pheno-
type varies. Mice with a viable yet strong loss of function allele
BubR1H/H, which expresses only 10–20% of BubR1 protein com-
pared with wild type, demonstrated that near complete loss of
BubR1 function results in cellular senescence and a premature
aging phenotype at the whole animal level (Baker et al., 2004;
Matsumoto et al., 2007). The premature aging is at least in part
dependent on p16INK4A expression (Baker et al., 2008); some of
the premature aging phenotypes could be reversed by selectively
eliminating p16-expressing cells from tissues (Baker et al., 2011).
Mice with weaker alleles such as the haploinsufficient (BubR1−/+),
which expresses about 50% of the protein, developed apparently
normally and showed only a modest phenotype, although reduc-
tion of overall lifespan was reported (Dai et al., 2004; Wijshake
et al., 2012). When challenged with Azoxymethane (AOM), a com-
monly used carcinogen for colon cancer studies, BubR1−/+ mice
showed significantly higher number and larger size of Aberrant
Crypt Foci (ACF), colonic precancerous lesions, than did wild-
type control; and they developed colon tumors (microadenoma)
(Dai et al., 2004). When combined with APCmin/+, BubR1−/+mice
showed a higher number of tumors in the colon (Rao et al., 2005).
These studies indicated that the haploinsufficiency significantly
enhances carcinogenesis, although BubR1 haploinsufficiency by
itself may not be a strong driver of carcinogenesis in the GI
tract.
SHUGOSHIN 1
Studies in yeast and humans demonstrated that a function of Sgo1
is as a protector of centromeric cohesion of mitotic chromosomes,
and that the loss of function results in genomic instability through
premature chromosome separation (Salic et al., 2004; McGuin-
ness et al., 2005; Wang et al., 2008; Iwaizumi et al., 2009). Later,
an unexpected role of Cohesin-Sgo1 complexes in centrosomal
integrity was demonstrated. A Cohesin-Sgo1 complex localized to
the centriole (a core structure of the centrosome) was involved in
engagement of the centriole, and Sgo1 depletion led to centriole
disengagement (Schöckel et al., 2011). In human colon cancers,
Sgo1 mRNA level is decreased, and siRNA-mediated inhibition of
Sgo1 in the colon cancer cell line HCT116 resulted in genomic
instability (Iwaizumi et al., 2009). Chromosome cohesion, a main
process that Sgo1 influences, is frequently defective in colon cancer
(Barber et al., 2008). Sgo1−/+mice developed apparently normally
(Wang et al., 2008). However, Sgo1 Mouse Embryonic Fibrob-
lasts (MEF) showed phenotypes reflecting the dual functions of
Sgo1, namely mitotic errors consistent with loss of chromosome
cohesion, and multiple centrosomes, consistent with a function in
centrosome integrity (Yamada et al., 2012). When challenged with
the carcinogen AOM, as in BubR1−/+mice, Sgo1−/+mice showed
significantly higher number and larger size of colonic precancer-
ous ACF lesions than did wild-type control, and they developed
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more tumors (Yamada et al., 2012). Interaction between APC and
Sgo1 mutations is being investigated (Yamada et al., unpublished).
Results from these two CIN mouse models indicate that the
mutations that create mitotic error-induced genomic instability
can enhance carcinogenesis in the GI tract.
WHY IS CIN SO PREVALENT IN CRC?
The high prevalence of CIN in colon cancer suggests two non-
mutually exclusive possibilities: (i) gene mutations causal to
colonic carcinogenesis are involved in CIN, and (ii) CIN by itself
may be either causal or promotional to colon carcinogenesis. As
discussed in previous sections, both possibilities have supporting
evidence. For the second possibility, some mechanistic insights
have been offered from mouse models. Once a high CIN condition
is introduced by mutation in the mitotic spindle checkpoint gene
Bub1 in mice, loss of chromosomes, and/or loss of heterozygosity
(LOH) of tumor suppressors is accelerated (Baker et al., 2009).
Such events would contribute to and/or facilitate carcinogenesis
directly.
In addition, by applying a concept from microbiology, it has
been argued that a high CIN condition may provide an adaptive
advantage in cancer evolution (Chandhok and Pellman, 2009).
With high CIN, a higher level of mutation and diversity is intro-
duced to cellular offspring, which would serve to adapt for survival,
as long as the new mutations do not immediately kill the cells.
Consistent with this notion, Benezra’s group first induced lung
tumors in mice via lung-specific doxycycline-mediated oncogenic
K-RAS activation; then, by shutting down the K-RAS expression,
they created a condition that mimics oncogene withdrawal and
resulted in tumor shrinkage and remission. The tumors recur with
a modest rate in a wild-type background. However, in mice hap-
loinsufficient for the spindle checkpoint component Mad2 that
show high genomic instability, a higher lung tumor recurrence
rate was observed (Sotillo et al., 2010). Several studies of human
cancers also concluded that patients with colon cancer with high
CIN show significantly poorer survival compared with patients
with colon cancer with low CIN or with high MIN (Watanabe
et al., 2012). Thus, high CIN is associated with or even causal to
high cancer recurrence and poor survival.
PRACTICAL APPLICATIONS OF GENOMIC INSTABILITY
STUDIES
In general, how humans and animals handle genomic instability
is still quite poorly characterized. Cells with a very high degree of
genomic instability may not be compatible with life; they may go
through destruction (e.g., apoptotic or necrotic death, phagocy-
tosis) or replicative death (e.g., senescence). However, cells with
modest genomic instability can survive. Such cells, particularly
those with progenitor/stem cell lineage, may be a latent source
of cancer if they are given the opportunity to accumulate further
mutations. Can we detect the presence of such cells? Can such
cells be removed selectively? The following section of this review
describes emerging approaches for addressing these questions:
(i) Gene markers indicative of genomic instability for screen-
ing and prognosis
High genomic instability is associated with gene expression
changes. Conversely, certain gene expression changes can
predict the presence of a high degree of genomic insta-
bility and can serve as genomic instability markers, which
can be detected with PCR-based tests. Carter et al., iden-
tified a signature of chromosomal instability from specific
genes whose expression was consistently correlated with total
functional aneuploidy in several human cancer types. Net
overexpression of this signature was predictive of poor clin-
ical outcome in 12 cancer data sets (Carter et al., 2006).
Similarly, with microarray-based expression analysis, Haber-
mann et al. (2009) identified 12-gene expression signatures
for genomic instability in breast cancer. The authors used
gene expression profiling of 48 breast cancer specimens that
differed profoundly in their degree of genomic instability
and identified a set of 12-genes that define the two groups
(genome stability vs. genomic instability). The gene signa-
tures include: nuclear RNA export factor 1 (NXF1), cDNA
DKFZp762M127, p28 (dynein, axonemal, light intermediate
chain 1), KIAA0882, v-myb, CDKN2A (p16INK4A), RAS-like,
estrogen-regulated, growth inhibitor (RERG), chemokine (C–
C motif) ligand 18 (SCYA18), aurora kinase A (STK15),
forkhead box A1 (HNF3A), and two unknown genes (Haber-
mann et al., 2009; Mettu et al., 2010). Expression of the gene
signatures was scored with a tumor database, and a signif-
icant correlation between high expression of the signatures
and poor prognosis in breast cancer was shown. In subse-
quent analysis, the 12-gene signature was tested with ovarian,
small cell lung carcinoma, and colorectal cancers. In all three
types of cancers, there was significant correlation between
the signature expression and cancer recurrence, suggested by
Kaplan–Meier survival curves over a 15-year period (Mettu
et al., 2010). Thus, the gene signatures may have application
as universal genomic instability markers. The functional sig-
nificance of the marker expression needs to be investigated,
and validation of the markers as drug targets needs to be
conducted for further translational application. However, this
information for CIN-associated gene expression signatures
can be used to develop a PCR-based gene expression analy-
sis kit applied to biopsy tissues (cancerous biopsy specimens
for prognosis, and possibly normal-looking tissues for risk
prediction).
(ii) Emerging attempts to target aneuploidy for cancer therapy
Aneuploidy is a form of genomic instability and a result of
CIN. Since genomic instability and aneuploidy are prevalent
among cancers, a notion has developed that targeting cells
with aneuploidy or genomic instability will selectively elim-
inate tumor initiating cancer cells. Amon’s group has been
characterizing aneuploid cells in yeast and in mice, and found
that aneuploidy leads to cell proliferation defects as well as
proteotoxic and energy stress (Williams et al., 2008; Tang et al.,
2011; Oromendia et al., 2012). The authors rationalized that
additional drug-mediated interference with pathways that
already are impaired in aneuploidy or that are essential for
cell viability may lead to lethality (synthetic lethal approach).
They demonstrated that 17-AAG, a drug that inhibits heat
shock protein 90 (HSP90), and aminoimidazole carboxam-
ide ribonucleotide (AICAR), a drug that induces adenosine
monophosphate kinase (AMPK) activation, show aneuploid
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cell-specific efficacy through p53-dependent cell death (Tang
et al., 2011). With independent lead studies, several HSP90
inhibitors including 17-AAG have entered Phase I/II clini-
cal trials and the evaluation is ongoing (Jhaveri and Modi,
2012; Neckers and Workman, 2012). These drugs may prove
effective against cancers that generate a high degree of ane-
uploidy without harming normal cells by exploiting specific
weaknesses in aneuploid cells.
CONCLUSION
It has been over a century since Theodore Boveri proposed a
relationship between carcinogenesis and aneuploidy in the early
twentieth century (Boveri, 2008; Holland and Cleveland, 2009).
During the past century, a number of genes involved in colonic
carcinogenesis and progression have been identified, and their
roles in generating genomic instability have been demonstrated, at
least in part. Transgenic mouse models have indicated that muta-
tions that create genomic instability also can be carcinogenic; and
novel use of the knowledge from genomic instability studies has
begun to be explored. Although colon cancer is a major lethal can-
cer at this moment, this situation should change in the future with
continuing efforts to translate basic science to the bedside.
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